Print

HVTN 041

A Phase I safety and immunogenicity trial of a combination vaccine (NefTat and gp120w61d) formulated with the adjuvant AS202A (GlaxoSmithKline Biologicals) given intramuscularly to HIV-1uninfected adult volunteers

Trial Details:

I Completed
HIV Vaccine Trials Network (HVTN) February 01, 2002
rgp120w61d Env gp120 B, Nef, Tat
rgp120w61d Protein
USA 84
NCT00027365
https://www.clinicaltrials.gov/ct2/show/NCT00027365